Fewer than a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it issues its inaugural advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance affirms that excess weight is a chronic disease that can be managed with thorough and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major barriers to widespread availability to the injections that can assist patients in reducing considerable body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Even in the present most favorable case, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice encourages nations and manufacturers to expand availability, through strategies including voluntary licensing.
Exclusive production rights on semaglutide – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Function
These medications replicate a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
Individuals typically see weight reduction in the initial weeks of starting on the once-weekly jabs.
Research indicates people may regain a significant portion within a year of halting the treatment, when their usual food cravings return.
To be carrying excess weight raises your likelihood for developing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity concerns people in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
